Advertisement
Australia markets closed
  • ALL ORDS

    8,416.60
    -57.70 (-0.68%)
     
  • ASX 200

    8,150.00
    -55.20 (-0.67%)
     
  • AUD/USD

    0.6845
    +0.0001 (+0.02%)
     
  • OIL

    74.83
    +1.12 (+1.52%)
     
  • GOLD

    2,680.90
    +1.70 (+0.06%)
     
  • Bitcoin AUD

    89,742.71
    +893.26 (+1.01%)
     
  • XRP AUD

    0.77
    +0.00 (+0.64%)
     
  • AUD/EUR

    0.6200
    +0.0003 (+0.04%)
     
  • AUD/NZD

    1.1024
    +0.0017 (+0.15%)
     
  • NZX 50

    12,619.94
    +47.28 (+0.38%)
     
  • NASDAQ

    19,793.34
    -9.24 (-0.05%)
     
  • FTSE

    8,241.75
    -40.77 (-0.49%)
     
  • Dow Jones

    42,011.59
    -184.93 (-0.44%)
     
  • DAX

    19,049.92
    +34.51 (+0.18%)
     
  • Hang Seng

    22,736.87
    +623.36 (+2.82%)
     
  • NIKKEI 225

    38,635.62
    +83.56 (+0.22%)
     

1 Beaten-Down Stock That Has a Lot to Prove in 2023

1 Beaten-Down Stock That Has a Lot to Prove in 2023

The past several years have been brutal for biotech company Bluebird bio (NASDAQ: BLUE). Shares of the gene-editing specialist are down by 85% since early 2020 as it has had to deal with clinical and regulatory setbacks, not to mention the marketwide headwinds that have impacted all equities.